MFS
BCLI

MSI Financial Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

MSI Financial Services’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$3K Hold
80
– – ﹤0.01% 3319
2016
Q3 		$3K Hold
80
– – ﹤0.01% 3311
2016
Q2 		$3K Hold
80
– – ﹤0.01% 3328
2016
Q1 		$3K Hold
80
– – ﹤0.01% 3370
2015
Q4 		$3K Buy
+80
New +$3.3K ﹤0.01% 3276

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MSI Financial Services's BCLI Position: Q4 2016 in Review

MSI Financial Services held its BRAINSTORM CELL THERAPUTC (BCLI) position steady in Q4 2016 at 80 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

MSI Financial Services first reported a position in BCLI in Q4 2015 and has held it in 5 quarters since. 27 funds tracked by Wall St. Rank hold BCLI as of Q4 2016.

  • MSI Financial Services held 80 shares of BRAINSTORM CELL THERAPUTC worth $3K as of Q4 2016.
  • MSI Financial Services left its BRAINSTORM CELL THERAPUTC share count unchanged in Q4 2016.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #3319 holding.
  • MSI Financial Services first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2015 and has held it in 5 quarters since.
  • 27 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.